SLXN (Silexion Therapeutics) Other Current Liabilities: $0.63 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLXN Silexion Therapeutics Corp SLXN
13 GF Score
Price $0.37
! 1 Warning Sign
View Full Analysis

What is Silexion Therapeutics Other Current Liabilities?

Silexion Therapeutics SLXN 13 Other Current Liabilities is $0.63 Mil as of Jun. 2026. GuruFocus rates SLXN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Silexion Therapeutics's other current liabilities for the quarter that ended in Jun. 2026 was $0.63 Mil.

Silexion Therapeutics's quarterly other current liabilities declined from Dec. 2025 ($0.88 Mil) to Mar. 2026 ($0.56 Mil) but then increased from Mar. 2026 ($0.56 Mil) to Jun. 2026 ($0.63 Mil).

Silexion Therapeutics's annual other current liabilities increased from Dec. 2023 ($0.41 Mil) to Dec. 2024 ($0.64 Mil) and increased from Dec. 2024 ($0.64 Mil) to Dec. 2025 ($0.88 Mil).

Silexion Therapeutics Other Current Liabilities Related Terms

Silexion Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Silexion Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silexion Therapeutics Other Current Liabilities Chart

Silexion Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
0.26 0.41 0.64 0.88

Silexion Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.72 0.88 0.56 0.63
SLXN
13GF Score
Silexion Therapeutics Corp SLXN
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Silexion Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.63 Mil mean?
Silexion Therapeutics (SLXN) has a Other Current Liabilities of $0.63 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Silexion Therapeutics.
Is Silexion Therapeutics' Other Current Liabilities too high?
Silexion Therapeutics' current Other Current Liabilities is $0.63 Mil. Overall, Silexion Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Silexion Therapeutics' Other Current Liabilities compare to DCOY and VRAX?
Silexion Therapeutics' Other Current Liabilities of $0.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Silexion Therapeutics. Silexion Therapeutics's current Other Current Liabilities is $0.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silexion Therapeutics stock overvalued right now?
Silexion Therapeutics (SLXN) has a current Other Current Liabilities of $0.63 Mil. The current Other Current Liabilities is $0.63 Mil. Silexion Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Silexion Therapeutics (SLXN), the current Other Current Liabilities is $0.63 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Silexion Therapeutics Business Description

Address 12 Abba Hillel Road, Ramat-Gan, ISR, 5250606
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
13GF Score

Get the complete analysis for SLXN

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.37
Price